COVID-19 Vaccines: BIO Pushes For EUA Guidance, While HHS’ Azar Downplays Its Importance

Guidance's release would provide regulatory clarity to scientists and strengthen public confidence in any vaccine authorized by the FDA, trade group says, but Alex Azar tells Congress the controversy over the unpublished document is overblown and making a ‘mountain out of a molehill.'

assorted molehills
To HHS' Alex Azar, the vaccine EUA guidance is a molehill turned into a mountain. • Source: Shutterstock

US Food and Drug Administration guidance on emergency use authorization for COVID-19 vaccines should be publicly released to provide regulatory clarity to scientists and researchers and strengthen public confidence in any vaccine authorized by the agency, the Biotechnology Innovation Organization says.

“All new FDA guidance should be finalized and communicated with those on the frontlines developing potential vaccines,” BIO president and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet